Skip to content

Effectiveness and safety of recombinant mussel mucin combined with medical dressings for post-mesotherapy skin repair in a clinical trial

Effectiveness and safety of recombinant mussel mucin combined with medical dressings for post-mesotherapy skin repair in a clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122374
Enrollment
Unknown
Registered
2026-04-13
Start date
2026-04-13
Completion date
Unknown
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Damage to skin barrier after aesthetic medicine treatment

Interventions

Test side:After mesotherapy treatment, the test product was applied to one side of the face according to a randomization table.
Control side:After mesotherapy treatment, the control product was applied to one side of the face according to a randomization table.

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age 35-60, healthy male and female ; 2. Willing to receive mesotherapy treatment ; 3. Consent with knowledge of the project and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. History of allergy to hyaluronic acid; 2. Treatment history of current skin diseases, severe allergies, treatments that may affect skin healing, facial beauty treatment history, etc. ; 3. Suffering from skin cancer or suspected skin cancer; 4. Received non-absorbent filler injections, laser therapy, facial implants, etc., in the past year ; 5. Has serious systemic diseases, such as heart disease, poor diabetes control, etc. ; 6. Women who are pregnant, breastfeeding, or plan to become pregnant during treatment ; 7. who have scar tissue or an abnormal healing history ; 8. Skin Sensitives ; 9. Participants with mental illness or other conditions that may affect treatment adherence ; 10. Clinical assessment deemed unsuitable to participate in the trial.

Design outcomes

Primary

MeasureTime frame
Loss of moisture through the epidermis;redness value;Security assessment;

Secondary

MeasureTime frame
moisture content of skin stratum corneum;L value;Skin recovery level;Satisfaction Score;

Countries

China

Contacts

Public ContactWang Xi

West China Hospital, Sichuan University

xierwang@126.com+86 28 8542 2075

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 23, 2026